Dr Christopher Mapperley

My research focuses on RNA biology in normal and malignant haematopoiesis, spanning from the discovery of novel therapeutic targets through to pre-clinical validation of novel compounds. I focus on identifying and exploiting vulnerabilities in acute myeloid leukaemia (AML) to develop more effective and less toxic treatment strategies. In parallel, I investigate how these pathways function in normal haematopoiesis, with a focus on defining therapeutic windows, minimising toxicity, and uncovering new approaches to enhance haematopoietic stem cell transplantation and regeneration.